CardioExchange Archive

February 24th, 2015

Increased Risk with NSAIDs Following Myocardial Infarction

Larry Husten, PHD

The cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and diclofenac  has been the subject of considerable uncertainty and controversy. Now a new study published in JAMA raises specific concerns about the safety of these drugs in the highly vulnerable population of people who have had a recent myocardial infarction. Using data from several linked national […]

---

February 13th, 2015

Can Clopidogrel Get Along with Proton Pump Inhibitors?

CardioExchange Editors, Staff

Are there clinically significant interactions between clopidogrel, proton pump inhibitors, and other drugs?

---

November 3rd, 2014

Selections from Richard Lehman’s Literature Review: November 3rd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include dual-antiplatelet treatment beyond one year after DES implantation, reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome, and more.

---

May 28th, 2014

Prescription Delay Following Stent Implantation Is a Common and Deadly Problem

Larry Husten, PHD

After receiving a stent, many patients delay or fail to fill their prescription for clopidogrel or another antiplatelet agent. Now, a study published in the Journal of the American Heart Association offers evidence that this problem is widespread and often leads to serious consequences. Researchers analyzed data from all stent implantations performed in British Columbia from […]

---

October 31st, 2013

Prolonged Dual Antiplatelet Therapy May Not be Necessary for Second-Generation Drug-Eluting Stents

Larry Husten, PHD

The precise duration of dual antiplatelet therapy (DAPT) following implantation of a drug-eluting stent (DES) has been the subject of considerable controversy. On the one hand, prolonged therapy may help prevent late stent thrombosis, which was particularly evident in first generation DESs. On the other hand, the risk of stent thrombosis may have diminished in […]

---

October 21st, 2013

Refining the Optimal Duration of Dual Antiplatelet Therapy After DES Implantation

Cheol-Whan Lee, MD and Seung-Jung Park, MD.,Ph.D

Cheol Whan Lee and Seung-Jung Park discuss their study group’s randomized trial comparing dual antiplatelet therapy with aspirin alone beyond 12 months after drug-eluting stent implantation.

---

September 19th, 2013

Clopidogrel’s Benefits Seen Mainly in Smokers

Nicholas Downing, MD

Clopidogrel appears to offer more protection against cardiovascular events among smokers than nonsmokers, according to a systematic review in BMJ. Researchers examined data from six randomized trials comparing clopidogrel (alone or with aspirin) with control treatments (namely, aspirin alone or lower-dose clopidogrel plus aspirin). Nearly 75,000 patients with established cardiovascular disease, 30% of whom were smokers, […]

---

September 1st, 2013

Pretreatment with Prasugrel Not Indicated in NSTEMI

Larry Husten, PHD

Pretreatment prasugrel for NSTEMI was not effective in the ACCOAST trial.

---

July 8th, 2013

Selections from Richard Lehman’s Literature Review: July 8th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a home-based walking intervention for those with PAD, BNP screening and collaborative care for HF, clopidogrel with aspirin in acute minor stroke or transient ischemic attack, and more.

---

June 26th, 2013

Some Patients with Minor Stroke or TIA May Benefit from Early Clopidogrel and Aspirin

Larry Husten, PHD

Some people with minor ischemic stroke or transient ischemic attack (TIA) may benefit from dual antiplatelet therapy with aspirin and clopidogrel, according to a large new study from China published in the New England Journal of Medicine. In the immediate period following a TIA or minor stroke, people are at high risk for having a major stroke. Aspirin […]

---